Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 36

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 36
---
 under the Securities Act of 1933, as amended, or the Securities Act. Cantor is not required to sell any specific dollar amount of shares, but will use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Cantor will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold. In connection with the sale of our common stock on our behalf, Cantor will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cantor with respect to certain liabilities, including liabilities under the Securities Act.

Investing in our securities involves a high degree of risk. You should read this prospectus and the information incorporated herein by reference carefully before you make your investment decision. See “Risk Factors” beginning on page S-6 of this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is ____________, 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                      | Page |
| About This Prospectus                                | S-1  |
| Cautionary Note Regarding Forward-Looking Statements | S-2  |
| Prospectus Summary                                   | S-3  |
| The Offering                                         | S-5  |
| Risk Factors                                         | S-6  |
| Use of Proceeds                                      | S-8  |
| Dilution                                             | S-9  |
| Description of Securities                            | S-10 |
| Plan of Distribution                                 | S-12 |
| Legal Matters                                        | S-13 |
| Experts                                              | S-13 |
| Where You Can Find More Information                  | S-13 |
| Incorporation of Certain Information By Reference    | S-13 |

You should rely only on the information we have provided or incorporated by reference in this prospectus or in any prospectus supplement. We have not authorized anyone to provide you with information different from that contained or incorporated